{"doi":"10.1001/jamanetworkopen.2025.7803","title":"Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA","abstract":"<jats:sec><jats:title>Importance</jats:title><jats:p>Rapidly acting therapeutics like 3,4-methylenedioxymethamphetamine (MDMA) are promising treatments for disorders such as posttraumatic stress disorder (PTSD). However, understanding who benefits most and the underlying neural mechanisms remains a critical gap. Stratifying individuals by neural circuit profiles could help differentiate neural, behavioral, and affective responses to MDMA, enabling personalized treatment strategies.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To investigate whether baseline stratification of individuals based on negative affect circuit profiles, particularly in response to nonconscious threat stimuli, can differentiate acute responses to MDMA.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>This randomized clinical trial, implementing a double-blinded, within-participant, placebo- and baseline-controlled design, was conducted at Stanford University School of Medicine between November 2, 2021, and November 9, 2022, for wave 1 data collection. Participants had used MDMA on at least 2 prior occasions, but not in the past 6 months, and had subthreshold PTSD symptoms and early life trauma but no current psychiatric disorders. Data were analyzed from March 1, 2023, to January 1, 2024.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Participants completed 4 visits: 1 baseline session followed by 1 placebo session and 2 MDMA sessions in a randomized order, totaling 64 visits. Baseline functional magnetic resonance imaging (fMRI) assessed the negative affect circuit using a nonconscious threat processing task (NTN).</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>Primary outcomes included activity and connectivity of amygdala and subgenual anterior cingulate cortex (sgACC) defining the negative affect circuit. Secondary outcomes were behavioral measures of implicit threat bias, likability of threat expressions, and affective assessments.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Sixteen participants (10 [63%] female; mean [SD] age, 40.8 [7.6] years) were stratified into subgroups with high and low levels of NTN activity in the amygdala (NTN<jats:sub>A+</jats:sub> [n = 8] and NTN<jats:sub>A−</jats:sub> [n = 8], respectively), based on a median split of baseline nonconscious threat-evoked fMRI responses. Following administration of the 120 mg of MDMA vs placebo, the NTN<jats:sub>A+</jats:sub> subgroup showed significant reductions in amygdala (contrast estimate [CE], −1.43; 95% CI, −2.60 to −0.27; Cohen <jats:italic>d</jats:italic>, −1.22; <jats:italic>P</jats:italic> = .02) and sgACC activity (CE, −1.48; 95% CI, −2.42 to −0.54; Cohen <jats:italic>d</jats:italic>, −1.56; <jats:italic>P</jats:italic> = .004), increased sgACC-amygdala connectivity (CE, 0.65; 95% CI, 0.02-1.28; Cohen <jats:italic>d</jats:italic>, 1.02; <jats:italic>P</jats:italic> = .04), and increased likability of threat expressions (CE, 14.38; 95% CI, 1.46-27.29; Cohen <jats:italic>d</jats:italic>, 0.86; <jats:italic>P</jats:italic> = .03) compared with the NTN<jats:sub>A−</jats:sub> subgroup.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>In this randomized clinical trial of MDMA’s acute profiles, 120 mg of MDMA acutely normalized negative affect circuit reactivity in participants stratified by heightened amygdala reactivity at baseline, demonstrating the potential of neuroimaging to identify prospective biomarkers and guide personalized MDMA-based therapies.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://clinicaltrials.gov/study/NCT04060108\">NCT04060108</jats:ext-link></jats:p></jats:sec>","journal":"JAMA Network Open","year":2025,"id":622189,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":230707,"name":"Laura M. Hack","orcid":"0000-0002-2647-4293","position":1,"is_corresponding":false},{"id":1065590,"name":"Claire Bertrand","orcid":"0000-0001-5595-0677","position":2,"is_corresponding":false},{"id":1065589,"name":"Rachel Hilton","orcid":"0000-0002-7943-2206","position":3,"is_corresponding":false},{"id":1607463,"name":"Nancy J. Gray","orcid":null,"position":4,"is_corresponding":false},{"id":1378954,"name":"Leyla Boyar","orcid":null,"position":5,"is_corresponding":false},{"id":1463922,"name":"Jessica Laudie","orcid":null,"position":6,"is_corresponding":false},{"id":653182,"name":"Boris D. Heifets","orcid":"0000-0003-1474-0379","position":7,"is_corresponding":false},{"id":324328,"name":"Trisha Suppes","orcid":"0000-0003-4560-6180","position":8,"is_corresponding":false},{"id":1607464,"name":"Peter J. van Roessel","orcid":null,"position":9,"is_corresponding":false},{"id":1607465,"name":"Carolyn I. Rodriguez","orcid":null,"position":10,"is_corresponding":false},{"id":169424,"name":"Karl Deisseroth","orcid":null,"position":11,"is_corresponding":false},{"id":817901,"name":"Brian Knutson","orcid":"0000-0002-7669-426X","position":12,"is_corresponding":false},{"id":326861,"name":"Leanne M. Williams","orcid":"0000-0001-9987-7360","position":13,"is_corresponding":false},{"id":772399,"name":"Xue Zhang","orcid":"0000-0003-0940-037X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA","abstract":"<jats:sec><jats:title>Importance</jats:title><jats:p>Rapidly acting therapeutics like 3,4-methylenedioxymethamphetamine (MDMA) are promising treatments for disorders such as posttraumatic stress disorder (PTSD). However, understanding who benefits most and the underlying neural mechanisms remains a critical gap. Stratifying individuals by neural circuit profiles could help differentiate neural, behavioral, and affective responses to MDMA, enabling personalized treatment strategies.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To investigate whether baseline stratification of individuals based on negative affect circuit profiles, particularly in response to nonconscious threat stimuli, can differentiate acute responses to MDMA.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>This randomized clinical trial, implementing a double-blinded, within-participant, placebo- and baseline-controlled design, was conducted at Stanford University School of Medicine between November 2, 2021, and November 9, 2022, for wave 1 data collection. Participants had used MDMA on at least 2 prior occasions, but not in the past 6 months, and had subthreshold PTSD symptoms and early life trauma but no current psychiatric disorders. Data were analyzed from March 1, 2023, to January 1, 2024.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Participants completed 4 visits: 1 baseline session followed by 1 placebo session and 2 MDMA sessions in a randomized order, totaling 64 visits. Baseline functional magnetic resonance imaging (fMRI) assessed the negative affect circuit using a nonconscious threat processing task (NTN).</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>Primary outcomes included activity and connectivity of amygdala and subgenual anterior cingulate cortex (sgACC) defining the negative affect circuit. Secondary outcomes were behavioral measures of implicit threat bias, likability of threat expressions, and affective assessments.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Sixteen participants (10 [63%] female; mean [SD] age, 40.8 [7.6] years) were stratified into subgroups with high and low levels of NTN activity in the amygdala (NTN<jats:sub>A+</jats:sub> [n = 8] and NTN<jats:sub>A−</jats:sub> [n = 8], respectively), based on a median split of baseline nonconscious threat-evoked fMRI responses. Following administration of the 120 mg of MDMA vs placebo, the NTN<jats:sub>A+</jats:sub> subgroup showed significant reductions in amygdala (contrast estimate [CE], −1.43; 95% CI, −2.60 to −0.27; Cohen <jats:italic>d</jats:italic>, −1.22; <jats:italic>P</jats:italic> = .02) and sgACC activity (CE, −1.48; 95% CI, −2.42 to −0.54; Cohen <jats:italic>d</jats:italic>, −1.56; <jats:italic>P</jats:italic> = .004), increased sgACC-amygdala connectivity (CE, 0.65; 95% CI, 0.02-1.28; Cohen <jats:italic>d</jats:italic>, 1.02; <jats:italic>P</jats:italic> = .04), and increased likability of threat expressions (CE, 14.38; 95% CI, 1.46-27.29; Cohen <jats:italic>d</jats:italic>, 0.86; <jats:italic>P</jats:italic> = .03) compared with the NTN<jats:sub>A−</jats:sub> subgroup.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>In this randomized clinical trial of MDMA’s acute profiles, 120 mg of MDMA acutely normalized negative affect circuit reactivity in participants stratified by heightened amygdala reactivity at baseline, demonstrating the potential of neuroimaging to identify prospective biomarkers and guide personalized MDMA-based therapies.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://clinicaltrials.gov/study/NCT04060108\">NCT04060108</jats:ext-link></jats:p></jats:sec>","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40305021","pmcid":"PMC12044494","openalex_id":"https://openalex.org/W4409985142","authors":[],"funders":[{"funder_name":"NIDA NIH HHS","grant_id":"P50 DA042012","title":null},{"funder_name":"NCATS NIH HHS","grant_id":"UL1 TR003142","title":null},{"funder_name":"National Institutes of Health","grant_id":"5UL1TR003142-03","title":"Stanford Center for Clinical & Translational Education and Research (Spectrum)"},{"funder_name":"National Institutes of Health","grant_id":"5P50DA042012-02","title":"Neural circuit dynamics of drug action"}],"total_grants":4,"fwci":14.8735,"citation_percentile":0.99301297,"influential_citations":0,"citation_trend":[{"year":2025,"count":5},{"year":2026,"count":6}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2833328/zhang_2025_oi_250287_1745261961.81633.pdf","host_type":"journal"},{"url":"https://doi.org/10.1001/jamanetworkopen.2025.7803","host_type":"GOLD"},{"url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2833328/zhang_2025_oi_250287_1745261961.81633.pdf","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40305021","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12044494","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12044494","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1001/jamanetworkopen.2025.7803","host_type":""}],"fields_of_study":["Psychedelics and Drug Studies","Forensic Toxicology and Drug Analysis","Cannabis and Cannabinoid Research","Medicine","Psychology","03 medical and health sciences","0302 clinical medicine","Humans","N-Methyl-3,4-methylenedioxyamphetamine","Female","Male","Adult","Double-Blind Method","Affect","Stress Disorders, Post-Traumatic","Magnetic Resonance Imaging","Brain","Hallucinogens","Middle Aged","Amygdala","Young Adult","Gyrus Cinguli"],"mesh_terms":["Adult","Affect","Amygdala","Brain","Double-Blind Method","Female","Gyrus Cinguli","Hallucinogens","Humans","Magnetic Resonance Imaging","Male","Middle Aged","Stress Disorders, Post-Traumatic","N-Methyl-3,4-methylenedioxyamphetamine","Young Adult"],"keywords":["MDMA","Affect (linguistics)","Psychology","Functional magnetic resonance imaging","Clinical psychology","Amygdala","Anterior cingulate cortex","Placebo","Major depressive disorder","Psychological intervention","Psychiatry","Medicine","Cognition","Neuroscience","Male","Adult","N-Methyl-3,4-methylenedioxyamphetamine","Brain","Middle Aged","Magnetic Resonance Imaging","Gyrus Cinguli","Stress Disorders, Post-Traumatic","Affect","Young Adult","Double-Blind Method","Hallucinogens","Humans","Female","Original Investigation"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T18:35:31.899428Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}